Summary.-The haematological responses of BDF1 mice were monitored after i.v. or i.p. inoculation of L1210 leukaemic cells. Although a marked decrease in haematocrit was observed in mice given L1210 by either route, the anaemia was most pronounced after the i.p. route. The leucocyte count was more markedly increased after i.v. inoculation than after i.p. inoculation. The number of platelets decreased following either route, but was more depressed by i.v. inoculation. When mice were treated with VM-26 on Day 4 after i.p. inoculation of 106 L1210 cells, the haematological responses were altered. VM-26 prevented the accumulation of haemorrhagic ascites fluid and the precipitous decline in haemotacrit. However, the number of leucocytes increased dramatically, most significantly during the 48 h before death. VM-26 caused a temporary restoration of platelet count to near baseline levels. By the time of death, however, a second decrease in platelets had occurred. The results suggest that the haematological response of mice to L1210 leukaemic cells varies according to the route of inoculation, and that these tumour-induced haematological responses of the host can be modified by treatment with VM-26.
HAEMATOLOGICAL CHANGES of ill-defined aetiology follow the inoculation of mice with transplantable tumours (Law et al., 1.949; Harriss & Hoelzer, 1974) and are frequently associated with human neoplasia . Dyscrasias may be capable of altering the therapeutic index of oncolytic drugs that as a group generally depress haemopoiesis . BDF1 mice inoculated with either L1210 or L5178Y ascites tumour cells, or with diffusion chambers containing L1210 cells, rapidly developed thrombocytopenia (Hacker et al., 1977) . Within 24 h of i.p. inoculation of these transplantable tumours, the platelet count decreased and continued to do so until the count was less than 20% of normal. The platelet count remained depressed until death.
The present study further examines the haematological response of mice to transplantable tumour lines, and reports a 49 tumour-induced decrease in haematocrit after inoculation of L1210 cells. Changes in the haematocrit ratios and platelet counts in mice after inoculation of L1210 and treatment with VM-266 (4'demethylepipodophyllotoxin 9-(4,6-0-2-thenylidine-B-D-glucopyranoside; NSC-122819) are then related to drug-induced changes in the leucocyte counts and to the course of the leukaemia. Drug preparation.-VM-26 (16 mg) was dissolved in 0 1 ml of dimethyl sulphoxide; subsequently, and in sequence, 1 ml of Tween 80R and 8 9 ml of 0.90o NaCl were added. This drug preparation was diluted with a similarly prepared vehicle to permit i.p. injection of various doses in a volume of 0 01 ml/g body wt.
Haematological measurerments.-Blood Awas obtained from the retro-orbital sinus using heparinized capillary tubes (Clay-Adams, Parsippany, N.J.). Twenty ,ul of blood for platelet and leucocyte determinations were removed from the capillary tube and placed in a Unopette (Becton-Dickson, Rutherford, N.J.) containing 1-98 ml of 1% ammonium oxalate. Platelets were counted under phase microscopy by the method of Brecher & Cronkite (1950) . Total number of nucleated blood cells, hereafter referred to as leucocytes, were counted in the manner described by Wintrobe et al. (1974) . The remainder of the blood in each capillary tube was centrifuged for determination of the PCV (Wintrobe et al., 1974) . Specimens of blood were obtained on alternate days from mice to avoid haematological depression from sampling.
RESULTS
Mice inoculated with 106 L1210 ascites tumour cells i.p. lived an average of 7-2 + 0-6 days and died with an accumulation of haemorrhagic ascites fluid containing tumour cells. Increasing numbers of erythrocytes were seen in the peritoneal cavity from Day 3. The mean life span of mice given 106 L1210 cells i.v. was 5-5 + 0 5 days. No haemorrhagic ascites fluid was seen in mice after i.v. inoculation.
The time of onset in the depression of the haematocrit was related to the number of L1210 cells inoculated i.p. (Fig. la) . Regardless of the number of cells inoculated, however, animals died shortly after the haematocrit decreased to -015. The rate of decrease in haematocrit was proportional to the number of cells inoculated (Fig. lb) . Regression equations for the rate of depression intersect at 16 h, regardless of inoculum size. This intersection suggests that the various inocula began to depress the haematocrit simultaneously, but several days elapsed before a significant decrease was observed.
The in the leucocyte count were accompanied by the appearance of leukaemic lymphoblasts. The platelet count of mice decreased after inoculation of L1210 cells by either route (Fig. 4) therapy until Day 4, we were able to monitor the haematological response of the host both before and after VM-26 treatment. The mean lifespan of treated animals was related to the dose of VM-26, and ranged from 86 + 0 5 days to 11*6 + 0 5 days. Preliminary studies indicated that VM-26 given at these doses to nontumour-bearing mice had no effect upon the haematological parameters of mice. Drug treatment modified the tumoura INTRAVENOUS induced decrease in haematocrit (Fig. 5a ). The elevation of leucocyte count in tumour-bearing mice was delayed 2-4 days by drug treatment (Fig. 5b) . The delay before the number of leucocytes increased was directly related to the dose of VM-26. At death, the leucocyte count in VM-26-treated mice was between 60 and 70 x 109/1, resembling that in mice inoculated by the i.v. route.
By Day 4, the platelet count of tumourbearing mice was maximally depressed. Within 24 h after VM-26 treatment, the platelet count had started to recover (Fig. 5c) . The increase in platelet count was directly related to the dose of VM-26. Regardless of VM-26 dose, however, the platelet count began to decrease on Day 8, and by death was less than in untreated mice.
DISCUSSION
The present studies, as well as the earlier report (Hacker et al., 1977) indicate that the haematological responses induced in the host by L1210 tumour cells would complicate many forms of oncolytic chemotherapy. In particular, sensitivity of the host to the toxicity of oncolytic drugs should be increased by the thrombocytopenia and anaemia induced by the tumour. Similar tumour-induced haematological responses were reported earlier by Harriss & Hoelzer (1974) after the inoculation of rats with myelomonocytic leukaemia L5222. Recently Jackson et al. (1980) have presented evidence that the thrombocytopenia induced by L1210 leukaemia results primarily from shortened platelet survival and organ pooling.
Although intra-abdominal haemorrhage undoubtedly contributed to the depression of the haematocrit after i.p. inoculation of L12 10, the haematocrit was also depressed after i.v. inoculation. The rate of depression of the haematocrit was related to the number of tumour cells inoculated i.p. However, when we assumed a doubling time of 12 h for L1210 cells (Skipper et al., 1965 ) the change in the haematocrit correlated inversely with the calculated number of tumour cells. Austin et at. (1979) teported recently that the L1210 leukaemia suppresses mouse erythroid colony formation, which may in part explain the anaemia in L1210-bearing mice.
The present studies confirm the report by Skipper et al. (1965) that i.v. inoculation of L1210 cells produced a higher leucocyte count than a similar inoculum injected i.p., and that i.v. inoculation is not accompanied by the accumulation of ascites associated with i.p. inoculation.
The haematocrit, leucocyte and platelet changes associated with i.p. L1210 inoculation were modified by delayed treatment with VM-26, to mimic the changes after i.v. inoculation. These results suggest that VM-26 killed the peritoneal cells but had a much less powerful effect on systemic cells. Therefore, the progress of the disease more closely resembled that after the i.v. route of inoculation. Initially, VM-26 blocked the expected decrease in haematocrit, and these values never decreased as expected after i.p. inoculation. At death, mice lacked the accumulation of bloody ascites normally associated with i.p. inoculation. Examination of the leucocyte counts after treatment with VM-26 confirmed the suspected change in course of the leukaemia; the increase in leucocyte count more closely resembled the pattern associated with i.v. inoculation than i.p. inoculation. Although i.p. treatment with VM-26 permitted a temporary recovery in the platelet counts, these counts subsequently decreased before death to a level below that associated with i.p. inoculation, and were similar to the level associated with i.v. inoculation. The potential significance of these observations is that tumourinduced haematological responses by the host may be useful in monitoring the effectiveness of chemotherapy, in selecting subsequent treatment, and in confirming the cause of death after treatment of mice inoculated with L1210 cells.
The present observations are of significance in planning protocols for delayed treatment of mice inoculated with L1210 ascites cells. The observations indicate that protocols for delayed treatment of L1210 cells should incorporate a chemotherapeutic phase, similar to induction therapy for acute lymphoblastic leukaemia in man, to reverse the thrombocytopenia and, if possible, the anaemia that is induced by the transplantable tumour. Although our data relate anaemia to the number of tumour cells calculated to be present, chemotherapy did not restore a normal PCV. The reason for the failure to recover a more normal PCV is unknown, though a similar PCV pattern was seen during spontaneous recovery of the platelet count after inoculation of L5178Y cells (Hacker et al., 1977) . Our preliminary studies with these doses of VM-26 did not alter the haematocrit of tumour-bearing animals. It is possible that there was insufficient time between treatment and subsequent progression of the disease to allow recovery of the PCV by erythropoiesis.
The drug-induced changes in the leucocyte count provide a simple method for monitoring the response of leukaemia to an anticancer drug. In the present studies, all doses of VM-26 markedly reduced the population of ascites tumour cells in mice given L1210 cells i.p. On the other hand, the peripheral-blood leucocyte count of mice inoculated i.p. with L1210 and treated with VM-26 subsequently increased into the range observed after i.v. inoculation. It is too early to know whether the leucocyte count will predict generally for relapse by systemically located cells. However, the present data do suggest that with VM-26 treatment conversion of L1210 inoculated i.p. into the systemic form associated with i.v. inoculation occurred. This conversion of disease states could lead to a 10-fold error in estimation of the fraction of cells killed by an oncolytic agent. This estimate is based on the fact that i.v. inoculation reduced life-span by about 2 days in comparison with an equivalent number of tumour cells inoculated i.p., a period of time that is about equivalent to a 10-fold variation in the number of cells inoculated i.p. (Skipper et al., 1965) .
